Skip to main content
Log in

CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population

  • Pharmacogenetics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

There is considerable variability in the individual pharmaceutical dosages required to achieve optimal therapeutic effects, which may be due to environmental or genetic factors. The objective of this study was to test the presence of the CYP2C9*3 allelic variant in the Chinese population and to investigate the association of this variant with both metabolism and therapeutic efficacy of irbesartan on essential hypertension.

Methods

In this study, we enrolled 711 subjects from Taihu County and 376 subjects from Dongzhi County in Anhui Province, China. All subjects received a single oral dose of 150 mg irbesartan daily for 28 days. The plasma concentration of irbesartan at 24 h after dosing on the 27th day and at 6 h after dosing on the 28th day was detected using fluorescence-high-performance liquid chromatography. CYP2C9 genotypes were determined using polymerase chain reaction—restriction fragment length polymorphism.

Results

No CYP2C9*2 allele was found in 235 Chinese samples and was removed from further study. The mean frequency of the CYP2C9*3 allele was 3.65%, while no CYP2C9*3/*3 genotype was detected. Multiple linear regression analyses revealed that the CYP2C9*3 allele carriers had significantly higher irbesartan concentrations in plasma at 6 h (Taihu: P<0.0001; Dongzhi: P=0.03) and 24 h (Taihu: P<0.0001; Dongzhi: P=0.00013) after dosing. No significant association was found between the CYP2C9*3 allelic variant and the therapeutic effect of irbesartan on essential hypertension.

Conclusion

Our study suggests that the CYP2C9*3 plays an important role in the metabolism of irbesartan and/or is in linkage disequilibrium with another potential CYP2C9 allele, both of which possibly modify the pharmacokinetics of irbesartan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Babaoglu MO, Yasar U, Sandberg M, Eliasson E, Dahl ML, Kayaalp SO, Bozkurt A (2004) CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 60(5):337–342

    Article  PubMed  CAS  Google Scholar 

  2. Bhasker CR, Miners JO, Coulter S, Birkett DJ (1997) Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 7:51–58

    Article  PubMed  CAS  Google Scholar 

  3. Bourrié M, Meunier V, Berger Y, Fabre G (1999) Role of Cytochrome P-450 2C9 in irbesartan oxidation by human liver microsomes. Drug Metab and Dispos 27(2):288–296

    Google Scholar 

  4. Cazaubon C, Gougat J, Bousquet F, Guiraudou P, Gayraud R, Lacour C, Roccon A, Galindo G, Barthelemy G, Gautret B (1993) Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 265:826–834

    PubMed  CAS  Google Scholar 

  5. Chando TJ, Everett DW, Kahle AD et al (1998) Biotransformation of irbesartan in man. Drug Metab Dispos 26(5):408–417

    PubMed  CAS  Google Scholar 

  6. Crespi CL, Miller VP (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: Cytochrome P450 oxidoreductase. Pharmacogenetics 7:203–210

    Article  PubMed  CAS  Google Scholar 

  7. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI (2001) Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African-Americans. Mol Pharmacol 60:382–387

    PubMed  CAS  Google Scholar 

  8. Fierens FLP, Vanderheyden PML, De Backer J-P, Vauquelin G (1999) Insurmountable angiotensin AT1 receptor antagonist: the role of tight antagonist binding. Eur J Pharmacol 372:199–206

    Article  PubMed  CAS  Google Scholar 

  9. Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K, Ohman KP, Nystrom F, Melhus H (2002) The CYP2C9 genotype predicts the blood pressure response to irbesartan: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol(SILVHIA) trial. J Hypertens 20(10):2089–2093

    Article  PubMed  CAS  Google Scholar 

  10. Hans R, Brunner (1997) The new angiotensin II receptor antagonist, irbesartan. pharmacokinetic and pharmacodynamic considerations. Am J Hypertens 10:311S–317S

    Article  PubMed  Google Scholar 

  11. Ho PC, Abbott FS, Zanger UM, Chang TK (2003) Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J 3(6):335–342

    Article  PubMed  CAS  Google Scholar 

  12. Klose TS, Blaisdell JA, Goldstein JA (1999) Gene structure of CYP2C8 and extrahepatic distribution of the hyman CYP2Cs. J Biochem Mol Toxicol 13:289–295

    Article  PubMed  CAS  Google Scholar 

  13. Lee CR, Goldstein JA, Pieper JA(2003) Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251–263

    Article  Google Scholar 

  14. Miners JO, Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525–538

    Article  PubMed  CAS  Google Scholar 

  15. Perrier L, Bourrie M, Marti E (1994) In vitro N-glucuronidation of SR 47436(BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. J Pharmacol Exp Ther 271:91–99

    PubMed  CAS  Google Scholar 

  16. Reeves RA, Lin CS, Kassler-Taub K, Pouleur H (1998) Dose-related efficacy of irbesartan for hypertension. Integrated Anal Hypertens 31(6):1311–1316

    CAS  Google Scholar 

  17. Scordo MG, Pengo V, Spina E (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphism on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72:702–710

    Article  PubMed  CAS  Google Scholar 

  18. Sim SC, Ingelman-Sunberg M, Daly AK et al (2005) Human cytochrome P450 (CYP) allele nomenclature committee (website); http://www.imm.ki.se/CYPalleles/

  19. Sullivan-Klose TH, Ghanayem BI, Bell DA et al (1996) J.A. The role for the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341–349

    Article  PubMed  CAS  Google Scholar 

  20. Takahashi H, Echizen H (2001) Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 40:587–603

    Article  PubMed  CAS  Google Scholar 

  21. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K (2000) CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10:95–104

    Article  PubMed  CAS  Google Scholar 

  22. Takahashi H, Wilkinson GR, Caraco Y et al (2003) Population differences in (S)-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese. Clin Pharmacol Ther 73:253–263

    Article  PubMed  CAS  Google Scholar 

  23. Timmermans PBMWM, Smith RD (1994) Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur Heart J 15(Suppl D):79–87

    PubMed  CAS  Google Scholar 

  24. Vachharajani NN, Shyu WC, Chando TJ, Everett DW, Greene DS, Barbhaiya RH (1998) Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. J Clin Pharmacol 38(8):702–707

    PubMed  CAS  Google Scholar 

  25. Vachharajani NN, Shyu WC, Smith RA, Greene DS (1998) The effects of age and gender on the pharmacokinetics of irbesartan. Br J Clin Pharmacol 46(6):611–613

    Article  PubMed  CAS  Google Scholar 

  26. Wen SY, Wang H, Sun OJ, Wang SQ (2003) Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray. World J Gastroenterol 9(6):1342–1346

    PubMed  CAS  Google Scholar 

  27. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha IJ, Shin JG (2001). Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 51:277–280

    Article  PubMed  CAS  Google Scholar 

  28. Yu BN, Luo CH, Wang D, Wang A, Li Z, Zhang W, Mo W, Zhou HH (2004) CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta 348(1–2):57–61

    Article  PubMed  CAS  Google Scholar 

  29. Zhang S, Liu P, Jiang S, Hong X, Xing H, Xu X (2005) Association of cigarette smoking with steady-state plasma concentration of irbesartan in male Chinese with hypertension. Methods Find Exp Clin Pharmacol 27(3):173–178

    Article  PubMed  CAS  Google Scholar 

  30. Zhao F, Loke C, Rankin SC et al (2004) Novel CYP2C9 genetic variants in Asian subjects and their influence on Maintenance warfarin dose. Clin Pharmacol Thr 76(3):210–219

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported in part by Anhui Provincial Ministry of Education, Anhui Medical University Biomedical Institute. We would like to thank the faculty and staff of the Anhui Medical University and of the Program of Population Genetics at Harvard School of Public Health. We are also grateful to all study participants and their families for their assistance and cooperation. We would like to thank Dr. Scott Venners and Dr. Xiaobin Wang for their careful editing of the manuscript. This study was conducted in accordance with the current regulations of People’s Republic of China and was approved by the institutional review board at Anhui Medical University. None of the authors claims any conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Xiping Xu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hong, X., Zhang, S., Mao, G. et al. CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol 61, 627–634 (2005). https://doi.org/10.1007/s00228-005-0976-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-005-0976-8

Keywords

Navigation